BRAF and cholangiocarcinoma: In the phase II ROAR basket trial, dual targeting with dabrafenib, a BRAF inhibitor, and trametinib, an MEK inhibitor shows promising activity in patients with BRAF V600E mutated locally advanced, metastatic or recurrent CCA or GBC with an ORR of 42% [76].